Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.

Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26. doi: 10.1007/s00280-011-1584-1. Epub 2011 Feb 17.

PMID:
21327930
2.

Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.

Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.

Oncology. 2012;83(2):57-66. doi: 10.1159/000338795. Epub 2012 Jun 29.

PMID:
22760079
3.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
4.

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH.

Invest New Drugs. 2010 Jun;28(3):343-9. doi: 10.1007/s10637-009-9265-1. Epub 2009 May 15.

PMID:
19444385
5.

Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).

Roehrig S, Wein A, Albrecht H, Konturek PC, Reulbach U, Männlein G, Wolff K, Ostermeier N, Hohenberger W, Hahn EG, Boxberger F.

Med Sci Monit. 2010 Mar;16(3):CR124-131.

PMID:
20190682
6.

Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.

Gibson MK, Holcroft CA, Kvols LK, Haller D.

Oncologist. 2005 Feb;10(2):132-7.

7.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.

Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.

PMID:
18391598
8.

Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.

El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA.

J Clin Oncol. 2003 Aug 1;21(15):2920-5.

PMID:
12885810
9.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
10.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
11.

A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.

Okusaka T, Ishii H, Funakoshi A, Ueno H, Furuse J, Sumii T.

Jpn J Clin Oncol. 2006 Sep;36(9):557-63. Epub 2006 Jul 26.

PMID:
16870696
12.

Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.

Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J.

Cancer Chemother Pharmacol. 2015 Mar;75(3):457-64. doi: 10.1007/s00280-014-2665-8. Epub 2014 Dec 30.

PMID:
25547407
14.

Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.

Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V.

JOP. 2006 Jul 10;7(4):349-60.

15.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
16.

Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.

Cereda S, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Brioschi M, Nicoletti R, Villa E.

Chemotherapy. 2011;57(2):156-61. doi: 10.1159/000324865. Epub 2011 Mar 31.

PMID:
21454973
17.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.

PMID:
11072167
18.

Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.

Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J, Hossfeld DK.

Anticancer Drugs. 2004 Jul;15(6):575-9.

PMID:
15205599
19.

Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.

Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK.

Eur J Surg Oncol. 2007 Sep;33(7):843-8. Epub 2007 Jan 5.

PMID:
17207959
20.

A phase II trial of 5-fluorouracil, leucovorin and mitomycin C in patients with advanced gastric cancer.

Kim SR, Yuh YJ, Sohn BS, Yang SH.

Tumori. 2011 Nov-Dec;97(6):698-703. doi: 10.1700/1018.11084.

Supplemental Content

Support Center